NHS 999 staff quitting and suffering burnout over ‘pressure' of calls
NHS 999 staff are quitting and suffering burnout caused by the 'relentless pressure' of calls, according to new research.
Figures obtained by Unison from ambulance services showed high turnover rates among call handlers, which staff say are often over a lack of support and the non-stop, often distressing, calls that force many to take sick leave.
A report launched at the union's annual conference in Liverpool today revealed the toll taken on the workforce, with more than a quarter of NHS ambulance control room staff quitting their jobs over the past three years.
According to the research, more than half a million days were lost to call handler illness in the three years from April 2021.
The figure for 2023/24 alone was 166,940 – the equivalent of more than a month of sick leave for each 999 call handler.
The union says high staff turnover and increased sickness absences are having a negative impact on patients.
It often means people are having to wait longer for 999 staff to answer calls or for their emergency to be properly assessed and dealt with.
Unison general secretary Christina McAnea said: 'These findings paint a bleak picture of the conditions faced by 999 control room staff.
'TV programmes about ambulance services don't show things as they really are. Call handlers are under immense pressure, making split-second decisions that directly affect lives.
'They handle relentless calls, often from people in distress, while dealing with complex emergencies and with limited resources.
'Despite their crucial role, 999 call handlers frequently face emotional strain and operate in an environment where support is sometimes lacking. The job is rewarding, but the challenges behind the scenes are far greater than most people realise.
'It's bad for morale and for patients when so many staff quit or are burnt out. Callers who dial 999 need to know the person picking up the phone is ready to deal with their crisis.
'Ambulance employers must do more to protect the health and wellbeing of staff who provide such high stakes support.
'This would help create a more stable emergency service that can retain the skills and experience of emergency call handlers, and persuade people to stay in the job for longer.'
An NHS spokesperson said: '999 call handlers play an essential role as the first point of contact in emergencies and the NHS is taking steps to help staff deal with record levels of pressure including providing a range of health and wellbeing support.
'But we know there is more to do and the health service is committed to tackling burnout by continuing to offer more flexible working options.'
A Department of Health and Social Care spokesperson said: 'One of the biggest stress factors for 999 call handlers are delays to call outs, which is why we will put almost 500 new ambulances on the roads as part of our wider urgent and emergency care plan to improve the speed and quality of care for those needing urgent or emergency treatment.
'We are also working with the NHS to support staff mental health, through occupation health provision, counselling and employee support programmes.'
The data was from 11 ambulance trusts.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
School pioneers project to help SEND pupils
A Sheffield school has received government support so pupils with special educational needs and disabilities (SEND) find it a calmer and happier place to learn. Carfield Primary School at Meersbrook was one of 1,200 schools nationwide chosen to take part in a £9.5m government scheme. The programme brings together teachers, health professionals and parents to make small changes at schools, such as staggering lunch breaks so they are less busy. One mum, Abi, praised the changes, saying her son had since made new friends and was "more confident in his speech". The government said some neurodivergent children were highly sensitive to loud noises or bright lights, leading to sensory overload which made it difficult to learn. Some had difficulty understanding social cues, could not manage their time or experienced hyperactivity which could make behaviour challenging. Carfield deputy head teacher Bethan Arthur said occupational therapists and speech and language professionals suggested how the school could adapt to help SEND pupils. Ms Arthur, who is also one of three Special Educational Needs Coordinators (SENCO), said: "One of the main issues is that our school is an old Edwardian building and that brings sensory difficulties for children, particularly those who have communication problems, because of the noise levels. "The support really helped us look how we can better support children within the school environment. "The therapists spent a whole day at school, in and out of classrooms, looking at areas such as dining rooms and identifying any issues they could potentially see. "We made simple changes - things such as installing noise cancelling barriers in the dining rooms have really helped. "We also now stagger our lunch times right through from reception all the way up to Year 6 so that lunch is much less busy. "For those children who find lunch time really overwhelming, we have put together small groups where we focus on taking turns and learning social skills with trained members of staff." Abi's son is seven and had struggled since he started school. She said: "At the age of three, we realised he wasn't speaking like other children. "He started school and the first thing we noticed was he didn't have any friends. "It was worrisome for me, because I feel a child should play with other children. "He had difficulty expressing himself, and had some difficulties in writing. "We don't have a formal diagnosis but we had tests and we have been to speech and language therapy sessions." Abi said the school came up with plans to help her son in class but she has also been using the techniques at home. "We have personal speech and language therapy support for him, which the school has been very helpful in putting together," she said. "It's been a very good experience working with staff and there is a committed teacher and a transition programme to prepare him for his next class. "We've seen a lot of progress and I'm really glad and happy about that." Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North Teaching support for SEND pupils gets £600k boost 'Urgent' action needed over exclusions - report Children face 'unacceptable waits' for SEND referral
Yahoo
2 hours ago
- Yahoo
Implantica announces successful UK RefluxStop™ Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals
VADUZ, Liechtenstein, June 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of treatment for acid reflux with its unique device RefluxStop™, a treatment field with 1 billion sufferers, announces the successful first UK National Users Meeting bringing together 21 top anti-reflux experts in UK last week. Surgeons exchanged their real-world experiences and delved into the positive National Institute for Health and Care Excellence (NICE) recommendations on using RefluxStop in NHS hospitals, opening a vast opportunity for RefluxStop procedures in patients with poor motility, representing up to 40-50%1 of the acid reflux (GERD/GORD) sufferers. Mr. Ahmed Ahmed, a renowned anti-reflux surgeon at the Imperial College Healthcare NHS Trust, says, "As more and more patients ask for RefluxStop, I'm very pleased to play a part in this unique opportunity to collaborate with my colleagues to offer the latest and greatest treatment options to our GERD patients, such as RefluxStop. I'm already seeing a rapidly growing demand for RefluxStop, in line with excellent outcomes achieved in my current RefluxStop patients. The recent positive NICE recommendations now allow the use of RefluxStop in NHS hospitals, which is a testament to the UK healthcare system's prioritization and focus on making the best treatments available to UK patients as soon as possible. On behalf of the GERD community, I would like to thank NICE and all involved stakeholders for their dedication to helping GERD patients who truly need effective treatment for this debilitating disease." Founder and CEO of Implantica, Dr. Peter Forsell, adds, "We sincerely thank and appreciate the world-leading healthcare policy advisory body, UK NICE, for their extensive and thorough review and announcement of the final positive recommendations for the RefluxStop™ procedure. Given how rampant GERD is in the UK, with up to 20% of the adult population struggling with the persistent discomfort and pain from the disease, the NICE recommendations for RefluxStop procedure couldn't be more appreciated among UK specialists, addressing the huge unmet need and treatment gap, especially for the GERD patients who have poor dysmotility.¹ Dr Forsell continues, "I'm truly impressed by the great enthusiasm for RefluxStop™ from the esteemed UK surgeons and other experts. Following the highly successful UK RefluxStop™ users meeting where several UK surgeons presented their excellent outcomes and patient satisfaction results, and now with the very supportive NICE recommendations, it's clear to me that RefluxStop™ will transform the reflux treatment landscape in the UK, and ultimately worldwide, in the coming future." 1Shih-Chi Ho et al., Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Digestive Diseases and Sciences, 2002. 47(3): 652-6 For further information, please contact: Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ The information was sent for publication, through the agency of the contact person set out above, on 17. June 2025, at 08:00 a.m. (CET). About Implantica Implantica is a MedTech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. About RefluxStop™ RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GERD involve encircling the food passageway to support the lower esophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit. In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux. Newsroom Community Media Contact: Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 This information was brought to you by Cision The following files are available for download: Implantica announces successful UK RefluxStopâ'¢ Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals logo transparent 1 8 ReluxStop Product View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Hemogenyx Pharmaceuticals PLC Announces Clearance to Proceed with Pediatric Expansion
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Regulatory Clearance to Proceed with Pediatric Expansion of HG-CT-1 Clinical Trial LONDON, UK / / June 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that the 30-day review period by the U.S. Food and Drug Administration (FDA) for the Company's previously submitted amendment to the clinical protocol of its ongoing Phase I trial of HG-CT-1 has concluded without a clinical hold. As a result, the Company is now cleared to proceed with the next steps required to initiate pediatric enrolment in the trial. The protocol amendment expands the eligibility criteria for the Phase I trial of HG-CT-1, Hemogenyx's proprietary CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML), to include children and adolescents with this aggressive and hard-to-treat disease. The Company will now move forward with Institutional Review Board (IRB) submissions and associated site activation procedures to enable the opening of pediatric cohorts. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"Regulatory clearance to proceed with the pediatric expansion of our HG-CT-1 clinical trial is a significant milestone. It reflects continued momentum in our development program and underscores our commitment to delivering innovative therapies to patients across age groups. This expansion broadens the potential impact and value of HG-CT-1 as we continue to advance toward key inflection points in the clinic. Importantly, it also reinforces the value of Company's robust intellectual property portfolio, which underpins our pipeline and supports long-term strategic growth." The Company will update the market as further progress is made in pediatric site activation and patient enrolment. Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Enquiries: Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@ Peter Redmond, Director SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Hemogenyx Pharmaceuticals PLC View the original press release on ACCESS Newswire